Skip to main content

InforMax Reports Fallen Revenues, Receded R&D, and Narrowed Loss in Q3

NEW YORK, Oct. 30 - InforMax today reported a 35-percent fall-off in revenue atop decreased R&D spending and a narrowed net loss.


For the period ended Sept. 30, InforMax, which two weeks ago said it will be acquired by Invitrogen, had total receipts amounted to $3 million, down from $4.7 million reported during the same quarter one year ago.


R&D spending, like all operating expenses, fell in the third quarter to $2 million compared with $2.5 million year over year, InforMax said.


Consequently, the company said third-quarter net loss narrowed to $5.2 million, or $.20 per share, from $5.4 million, or $.22 per share, during the same period one year ago.


InforMax said it had roughly $46.9 million in cash, cash equivalents, and investments available for sale as of Sept. 30.


Click here for more information.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.